{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"whMfz82Xw5\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/\">Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/aspira-womens-health-regains-nasdaq-compliance\/embed\/#?secret=whMfz82Xw5\" width=\"600\" height=\"338\" title=\"&#8220;Aspira Women\u2019s\u00a0Health\u00a0Regains Nasdaq Compliance&#8221; &#8212; Market Newsdesk\" data-secret=\"whMfz82Xw5\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) &#8212; Aspira\u00a0Women\u2019s Health Inc. (\u201cAspira\u201d\u00a0or \u201cthe Company\u201d)\u00a0(Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women\u2019s health diagnostic tools for gynecologic diseases, today\u00a0announced\u00a0that it received written notice from the Nasdaq Stock Market LLC (\u201cNASDAQ\u201d) on September 12, 2023 informing the Company that it has regained compliance with the market value of listed securities (\u201cMVLS\u201d) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the \u201cRule\u201d) for continued listing on the Nasdaq Capital Market. About\u00a0Aspira\u00a0Women\u2019s\u00a0Health\u00a0Inc.\u00a0 Aspira Women\u2019s Health Inc. is transforming women\u2019s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer.\u00a0\u00a0\u00a0 Our ovarian cancer risk assessment portfolio &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyMTMxMSM1ODExODkzIzUwMDA0NTYzNw=="}